Acamprosate is primarily utilized in the treatment of Alcohol Use Disorder (AUD) to support the patient's goal of continuous sobriety. The medication is relevant for use in the maintenance of abstinence in patients with alcohol dependence who are already abstinent when starting therapy.

---

Sustaining Long-Term Abstinence and Preventing Relapse

The medication may support the patient's likelihood of maintaining continuous abstinence from alcohol. It helps patients remain committed to sobriety by providing assistance during the chronic phase of alcohol dependence management.

Mitigating the Drive to Drink (Craving)

Acamprosate is commonly used to help manage the intrusive and intense craving for alcohol, which is a primary symptomatic challenge to recovery. By assisting with easing this psychological preoccupation, the treatment contributes to a patient's ability to cope more steadily with the urge to drink.

---

“This supportive relief contributes to easing the overall symptom load that challenges comfort during abstinence.”

Easing Protracted Discomfort in Early Sobriety

The treatment is relevant for managing the persistent, low-grade manifestations known as post-acute withdrawal symptoms (or protracted abstinence discomfort). By easing the psychological preoccupation, the treatment assists with maintaining functional stability, which may help patients cope more steadily with the urge to drink.

Quick Fact: Relief for Protracted Discomfort
This medication is relevant for managing the lingering symptoms that occur after the acute withdrawal phase, supporting stability in early and sustained recovery.

Who Can and Cannot Use Acamprol? (Acamprosate)

This section outlines the official eligibility and non-eligibility profiles for Acamprol based strictly on government regulatory documents.

Contraindications (Must Not Use)

Official labeling contraindicates Acamprol for patients with severe renal impairment (creatinine clearance leq 30 mL/min). It is also contraindicated for individuals with known hypersensitivity to acamprosate calcium or any of its components. Several regulatory agencies specify that the medicine is contraindicated for lactating/breastfeeding women.

Restricted or Conditional Use

Use is restricted for patients with moderate renal impairment (creatinine clearance 30–50 mL/min), which requires a mandated dose reduction. For pregnant individuals, use is conditional; the potential benefit must justify the potential risk to the fetus after a clinical risk-benefit assessment. Use is not established for those with severe hepatic impairment (Child-Pugh Classification C).

Age-Related Eligibility

The medicine is generally indicated for adults aged 18 to 65. Safety and efficacy have not been established for children and adolescents (under 18), and the drug is not recommended for use in this group. Similarly, due to lack of established data, it is not recommended for geriatric patients (65 years and older).

Interactions with other medicines and products

Acamprosate Calcium (Acamprol) demonstrates a low potential for clinically significant drug-drug interactions, primarily due to its pharmacokinetic profile.

Drug-Drug Interactions

The medication is not metabolized by the liver’s Cytochrome P450 (CYP) enzyme system and is excreted largely unchanged by the kidneys. This means Acamprosate has no documented inducing or inhibiting potential on major CYP enzymes, minimizing metabolic interaction risk.

Formal studies have examined co-administration with other medications relevant to the treatment of Alcohol Use Disorder (AUD) or related conditions:

Co-administered Substance	Official Interaction Outcome
Naltrexone	No need for dose adjustment, despite a documented increase in Acamprosate's plasma exposure (AUC and Cmax).
Disulfiram, Diazepam, Imipramine	Pharmacokinetics of both Acamprosate and these agents were unaffected.
Benzodiazepines	No evidence of additive Central Nervous System (CNS) depressant effects has been documented.

Drug-Food and Drug-Substance Interactions

Administration with food diminishes the oral bioavailability of Acamprosate, which is a key consideration for achieving adequate systemic drug exposure. In contrast, the co-administration of alcohol (ethanol) does not affect the pharmacokinetics of either Acamprosate or alcohol, as documented in regulatory reports.

The mechanism of action involves the central nervous system, specifically the modulation of major opposing neurotransmitter systems. Acamprol acts as a weak antagonist at the NMDA receptors (N-methyl-D-aspartate receptors), which are primarily involved in excitatory signaling. Concurrently, the compound functions as a positive allosteric modulator of GABAA receptors, enhancing the activity of the primary inhibitory neurotransmitter system.

This dual receptor action mitigates the excitotoxicity of the glutamatergic system (via NMDA antagonism) while facilitating the function of the GABAergic system. By modulating the balance between GABA and Glutamate signaling, the compound influences overall neuronal excitability and systemic electrophysiological stability. This targeted activity impacts the long-term physiological state of the central nervous system.

Instruction Map: How to use Acamprol — Official Administration Guidelines

Acamprosate calcium is provided as a 333 mg delayed-release, enteric-coated tablet for oral administration. The administration protocol is designed to ensure consistent systemic exposure.

Entity	Instruction
Route of administration	Oral (by mouth)
Standard Dosing Schedule	The standard daily dose is 1998 mg, administered as two 333 mg tablets taken three times daily (666 mg per dose).
Timing in relation to meals	Dosing with meals is suggested to support patient compliance.
Tablet Handling	Tablets must be swallowed whole and must not be crushed or chewed, a requirement of the delayed-release, enteric-coated formulation.

---

Use Protocol and Adjustments

Treatment is initiated as soon as possible after the period of alcohol withdrawal, once the patient has achieved abstinence. Treatment may be maintained even if the patient relapses to drinking, and the typical duration is up to one year.

Population-specific dosing adjustments apply to renal function: a reduced dose of one 333 mg tablet taken three times daily (999 mg total daily dose) is used for patients with moderate renal impairment (Creatinine Clearance 30-50 mL/min). The drug is not indicated for patients over 65 years of age. If a dose is missed, the missed dose should be skipped if it is near the time for the next scheduled dose, followed by a return to the regular regimen; double doses should be avoided.

---

Connection to the overall use protocol: These instructions define a divided-dose protocol reliant on the patient achieving and maintaining abstinence, with specific rules for administration, particularly regarding the tablet's structural integrity and necessary dose modification based on renal health.

Overview of Clinical Evidence

Acamprol (acamprosate) is a medication used in the comprehensive management of Alcohol Use Disorder (AUD) to help patients maintain abstinence after detoxification. Its clinical effectiveness has been the subject of numerous randomized, placebo-controlled trials and several systematic reviews globally.

International clinical trials have explored acamprosate's impact on relapse prevention. A re-analysis of several pivotal European studies demonstrated that a significantly higher percentage of patients achieved and maintained complete abstinence when treated with acamprosate plus psychosocial support, compared to placebo plus psychosocial support.

Efficacy and Outcomes

Research summaries and meta-analyses suggest that acamprosate can increase the likelihood of achieving abstinence following detoxification. However, the findings across all global studies, particularly those conducted in North America, have shown some mixed results regarding its effectiveness compared to placebo or other pharmacotherapies. While studies consistently support its role in maintaining abstinence, findings regarding its effect on reducing heavy drinking days (in patients who do relapse) are less conclusive.

Outcome Measure	Finding (vs. Placebo)
Complete Abstinence	Higher rates reported in multiple large European and some Asian trials.
Time to First Drink	Generally extended in treatment groups.
Reduction in Heavy Drinking	Mixed or limited evidence.

Mechanism of Action (Investigated)

Although the precise mechanism is not fully understood, preclinical and human studies have explored the theory that acamprosate helps to restore the balance between the excitatory neurotransmitter glutamate and the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain, which is often disrupted by chronic alcohol exposure. Research suggests it may interact with the NMDA receptor system.

Common questions about Acamprol (FAQ)

---

Q: How is Acamprol different from Naltrexone?

Acamprol is classified as a Central Nervous System (CNS) agent and a neuromodulator, meaning it works by influencing the balance of chemical messengers in the brain. Naltrexone, another medicine used for alcohol support, is classified as an opioid antagonist. Studies show that when taken together, no dose adjustments are typically needed.

Q: Are there any serious side effects associated with Acamprol?

Serious adverse events documented in clinical trials include suicidal ideation and suicide attempts. Additionally, severe hypersensitivity reactions, such as angioedema (swelling of the face or throat), are documented as a rare risk. These risks are documented in the official prescribing information.

Q: What happens if I stop taking Acamprol suddenly?

Acamprol is categorized as a Central Nervous System (CNS) agent, but authoritative sources state that it is not considered addictive. Unlike some other substances, Acamprol is reported not to cause withdrawal symptoms if the medication is stopped abruptly.

Q: What is the recommended duration of treatment with Acamprol, generally speaking?

According to official product information, the typical recommended duration of treatment with Acamprol is generally up to one year, as part of the overall management plan.

Q: Do clinical trials show that Acamprol reduces the risk of relapse?

Studies and official information indicate that Acamprol, when used with psychosocial support, can increase the chance of achieving and maintaining complete abstinence. Evidence indicates that it is generally associated with an extended time to the first drink.

Q: Is Acamprol only used in combination with counseling?

Official prescribing information states that Acamprol is used as part of a comprehensive psychosocial treatment program. It is not intended to be used as a stand-alone treatment.

Q: What is the maximum amount of time Acamprol can be taken for?

While regulatory documents do not define an absolute maximum time, the typical recommended duration of treatment specified in official product information is up to one year.

Q: How long does it usually take for Acamprol to start having an effect?

The onset of action is measured by reaching steady-state plasma concentrations, which is the consistent level the drug reaches in the body. According to regulatory pharmacokinetics data, this is typically achieved within five days of starting the dosing regimen.

Q: What food or beverages should be avoided when taking Acamprol?

Co-administration with food is reported to decrease the oral bioavailability of Acamprol. No specific food or beverage avoidance is mandated in official documents, but official information mentions that dosing with meals has been suggested to support compliance.

Q: Can Acamprol cause weight gain or weight loss?

Both weight gain and weight loss have been reported as adverse events in clinical trials. Weight gain is classified as a Common side effect, meaning it may affect between 1% and 10% of patients.

Q: What is the chemical name of the active ingredient in Acamprol?

The active substance is Acamprosate, which is delivered as the calcium salt. According to official chemical monographs, the formal chemical name of Acamprosate Calcium is Calcium 3-Acetamido-1-propanesulfonate.

Q: Has Acamprol been studied in adolescents?

Official labeling states that the safety and efficacy of Acamprol have not been established for children and adolescents, defined as individuals under 18 years of age.

Q: Is there a link between Acamprol and mood changes?

The medication's safety profile includes psychiatric side effects such as anxiety and depression classified as Common. Additionally, official prescribing information includes warnings about serious events of a suicidal nature.

Q: Does the time of day matter when taking Acamprol?

The official regimen requires the medication be taken as a divided dose, typically three times daily. Dosing with meals is suggested to support patient compliance, but no specific hours of the day are strictly mandated.

Q: Is it normal to have persistent headaches while taking Acamprol?

Headache is listed in the official safety documents as a Common adverse event. This means it has been reported to affect between 1% and 10% of patients in clinical trials.

Q: What are the most commonly reported reasons for discontinuing Acamprol in studies?

Diarrhea is classified as a Very Common side effect, meaning it may affect more than 1 in 10 people. It is frequently cited in clinical trial literature as one of the most common reasons for patients to discontinue taking the medication due to its bothersome nature.

Q: Are there any common reasons a person might be advised to stop taking Acamprol?

Official reasons for stopping treatment include the development of a severe hypersensitivity reaction, the presence of severe kidney impairment, or the occurrence of serious adverse events of a suicidal nature.

Q: Is Acamprol available in different strengths?

According to official regulatory documents regarding dosage forms and strengths, Acamprosate Calcium Delayed-Release Tablets are available containing only 333 mg of acamprosate calcium.

Q: Is Acamprol available as a generic medicine?

Yes, official records show that the FDA has approved generic versions of the brand name Campral (acamprosate calcium).

How to Store and Dispose of Acamprosate Calcium (Acamprol)

---

️ Storage Conditions

Acamprosate calcium tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product should be kept in its original, tightly closed container and must be protected from excessive moisture and heat. It is required to keep the medication out of the reach of children.

️ Disposal Instructions

Official regulatory guidance advises utilizing a drug take-back program for unused or expired tablets. If a take-back program is unavailable, patients may mix the medication with an undesirable substance (such as dirt or cat litter) before placing the mixture in a sealed bag and discarding it in the household trash. The medication must not be flushed down the toilet.